Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immuno Gene Therapy

Goyvaerts, Cleo; Kochan, Grazyna; Escors, David; Breckpot, Karine

doi:10.5772/17367

Cited by 2 publications

(2 citation statements)

References 268 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of these is the use of LVs to deliver cancer, viral or autoimmune antigens together with immune-modulating molecules to APCs, which subsequently induce the appropriate immune response, that is, immunity or tolerance, respectively. 36 Optimization of the safety and efficiency of the LVs used to modify APCs could make them an even more powerful tool for developing novel treatment modalities against various diseases.…”

Section: Discussionmentioning

confidence: 99%

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

et al. 2012

View full text Add to dashboard Cite

Lentiviral vectors (LVs) provide unique opportunities for the development of immunotherapeutic strategies, as they transduce a variety of cells in situ, including antigen-presenting cells (APCs). Engineering LVs to specifically transduce APCs is required to promote their translation towards the clinic. We report on the Nanobody (Nb) display technology to target LVs to dendritic cells (DCs) and macrophages. This innovative approach exploits the budding mechanism of LVs to incorporate an APC-specific Nb and a binding-defective, fusion-competent form of VSV.G in the viral envelope. In addition to production of high titer LVs, we demonstrated selective, Nb-dependent transduction of mouse DCs and macrophages both in vitro and in situ. Moreover, this strategy was translated to a human model in which selective transduction of in vitro generated or lymph node (LN)-derived DCs and macrophages, was demonstrated. In conclusion, the Nb display technology is an attractive approach to generate LVs targeted to specific cell types.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

et al. 2012

View full text Add to dashboard Cite

show abstract

“…DCs can either trigger effective immune responses or suppress them [56,57]. eir acquisition of tolerogenic activities takes place under speci�c circumstances.…”

Section: Tolerogenic Dcsmentioning

confidence: 99%

Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance

et al. 2012

Self Cite

View full text Add to dashboard Cite

Retroviral and lentiviral vectors have proven to be particularly efficient systems to deliver genes of interest into target cells, either in vivo or in cell cultures. They have been used for some time for gene therapy and the development of gene vaccines. Recently retroviral and lentiviral vectors have been used to generate tolerogenic dendritic cells, key professional antigen presenting cells that regulate immune responses. Thus, three main approaches have been undertaken to induce immunological tolerance; delivery of potent immunosuppressive cytokines and other molecules, modification of intracellular signalling pathways in dendritic cells, and de-targeting transgene expression from dendritic cells using microRNA technology. In this review we briefly describe retroviral and lentiviral vector biology, and their application to induce immunological tolerance.

show abstract

Dendritic Cells and Lentiviral Vectors: Mapping the Way to Successful Immuno Gene Therapy

Cited by 2 publications

References 268 publications

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells

Retroviral and Lentiviral Vectors for the Induction of Immunological Tolerance

Contact Info

Product

Resources

About